Julia R. Lazzari-Dean

Jun 14, 2024 | cell.com | Byrska-Bishop M |Karl Kumbier |Julia R. Lazzari-Dean

Highlights•Molecular ALS phenotype scores (MAPs) discriminate FUS fALS from healthy fibroblasts•Imaging and transcriptomics MAPs show strong concordance•Imaging MAPs quantify shifts of FUS ALS phenotype toward health upon FUS ASO treatmentSummaryAmyotrophic lateral sclerosis (ALS) is a rapidly progressing, highly heterogeneous neurodegenerative disease, underscoring the importance of obtaining information to personalize clinical decisions quickly after diagnosis.